Latest news with #spinalimplants
Yahoo
31-07-2025
- Business
- Yahoo
VB Spine Launches in Australia and New Zealand
Stryker's spinal implants business in Australia and New Zealand fully transitions to VB Spine and LifeHealthcare continues as exclusive distributor NEW YORK & SYDNEY, July 31, 2025--(BUSINESS WIRE)--VB Spine LLC ("VB Spine"), a global, family-led spine company dedicated to advancing patient outcomes, announced the completion of the sale of Stryker's spinal implants business in Australia and New Zealand. This milestone builds upon the formation of VB Spine on April 1, 2025, following the acquisition of Stryker's U.S. spinal implants business by Viscogliosi Brothers, LLC. It also marks VB Spine's first market entry outside the United States and establishes a direct presence in two fast-growing markets. VB Spine continues to have exclusive access to Stryker's Mako Spine and the Copilot automatic depth stop feature. This strategic partnership creates a strong foundation for VB Spine's continued growth, providing surgeons greater precision and improving patient outcomes. "From the start, our vision has been simple: put patients first and innovate boldly," said Marc Viscogliosi, co-CEO of VB Spine, speaking for his brothers and fellow co-CEOs Anthony and John Viscogliosi. "Today we take that vision global. By combining the passion of our family-run culture with LifeHealthcare's best-in-class surgeon support, we're opening a new chapter in spine care defined by access, outcomes, and possibility." LifeHealthcare, already the long-standing distributor for these products, will continue as the exclusive partner, providing uninterrupted product availability and clinical support for surgeons and their patients throughout Australia and New Zealand. Paul Petherbridge, CEO of LifeHealthcare, said, "We are pleased to announce our long-term collaboration with VB Spine. LifeHealthcare has represented this portfolio since 2010, providing clinicians and patients in Australia and New Zealand with reliable access to spinal instrumentation and implants through our experienced team. Our partnership with VB Spine aligns with our mission for Spine in ANZ: 'What matters to you drives us.' We look forward to working with the Viscogliosi brothers and the VB Spine team to offer innovative solutions and valuable education to our clinicians." Transition highlights All current spinal implant SKUs remain available through LifeHealthcare with no service interruption. Surgeons and hospitals will continue to work with their local LifeHealthcare representatives. VB Spine plans to attend Deformity Down Under (DDU) in Brisbane, which began as a surgeon-led initiative to foster collaboration, share knowledge, and improve outcomes in spine surgery. Forward-looking statements Certain statements in this release are forward-looking and are based on current expectations, forecasts, and assumptions. Actual results may differ materially due to regulatory, commercial, and operational risks. VB Spine disclaims any obligation to update forward-looking statements except as required by law. Transaction financing Viscogliosi Brothers, LLC and Viscogliosi Brothers Watermark Holdings LLC are equity investors in VB Spine. About VB Spine VB Spine LLC is the largest privately held spine company and among the largest family-owned medical technology companies in the world. With a comprehensive product portfolio and a large and growing global distribution network, VB Spine delivers specialized solutions that address critical needs in spine surgery and enhance patient outcomes. Focused on people, partnerships and operational excellence, VB Spine ensures healthcare professionals have access to the tools and resources needed to provide the highest standard of care. VB Spine is owned and led by the Viscogliosi Brothers. For more information on VB Spine, please visit About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at About LifeHealthcare Distribution Pty Ltd (Australia) and LifeHealthcare Ltd (New Zealand) LifeHealthcare, an EBOS MedTech company, is committed to providing patients in Australia and New Zealand with access to world-class medical devices and technology. Our goal is to ensure the long-term economic sustainability of the healthcare system. We offer a diverse range of products across various channels for surgical intervention, including but not limited to therapeutic areas such as Spine and Enabling Technology, Orthopaedics (Reconstruction, Extremities, and Regenerative Medicine), Plastics and Reconstructive Surgery, Neurovascular Intervention, Abdo-Pelvic Surgery, and Neurosurgery, among others. For more information about LifeHealthcare, please visit or About Viscogliosi Brothers Viscogliosi Brothers, LLC is a family-owned New York City-based family office dedicated to driving growth and innovation in the neuro-musculoskeletal industry. Established in 1999, the firm focuses on identifying and building groundbreaking innovations in healthcare, aiming to address unmet clinical needs, enhance patient outcomes, and drive cost efficiency in the healthcare system. Since its inception 26 years ago, Viscogliosi Brothers has founded, financed, operated and grown 43 businesses with operations and distribution across more than 80 countries. These businesses have positively impacted millions of patients with cutting-edge innovations in healthcare. The firm has led the transformation of the spine industry through its multiple businesses specifically including: Spine Solutions, Spine Next, Paradigm Spine, Simplify Medical, Centinel Spine, Companion Spine, Spine BioPharma and Woven Orthopedic Technologies, among others. For more information, visit About Viscogliosi Brothers Watermark Viscogliosi Brothers Watermark LLC is a New York City-based holding company specializing in investing in innovation within the MedTech sector. Founded in 2022, VBW is committed to creating alternative wealth for its shareholders while enhancing humanity's well-being. With a portfolio-driven investment mandate and strategic expertise, VBW supports its invested entities through financing and manufacturing capabilities. For more information, visit View source version on Contacts For media inquiries only: vbspinecommunications@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
03-07-2025
- Business
- Yahoo
Spineway : GMED approval for new production line dedicated to ESP prostheses - First production of LP-ESP intervertebral disc prostheses
Press release Ecully, July 3, 2025 – 6:30 GMED approval for new production line dedicated to ESP prostheses First production of LP-ESP intervertebral disc prostheses Spineway, a specialist in innovative implants for the treatment of severe spine disorders, announces that its subsidiary Spine Innovations has received GMED (French notified body) approval for its new production line dedicated to its LP-ESP and CP-ESP intervertebral disc prostheses. This approval is a significant strategic milestone for the Group, ensuring the manufacturing and supply of its innovative ESP prostheses. Located in La Rochelle, on the premises of a long-standing Spineway partner, the new line includes a clean room for injection operations. In line with the schedule1, the first LP-ESP prostheses went into production last month and the first implants from this new line should be available by the end of July. 'The approval of this new production line allows us to secure our supply chain while doubling our production capacity. It also reflects our industrial commitment in France and our desire to continue integrating the manufacture of spinal implants,' said Stéphane Leroux, CEO of Spineway. Find out all about Spineway at This press release has been prepared in both English and French. In case of discrepancies, the French version shall Available Tuesday through Thursday Solène Kennisspineway@ Press release of March 24, 2025 Attachment CP_SPW_Ligne_ESP_VDEF_EN
Globe and Mail
16-06-2025
- Business
- Globe and Mail
Aurora Spine Surpasses 1,500 Successful Surgeries Using DEXA-C™
Please click to view image CARLSBAD, CALIFORNIA, June 16, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation ('Aurora Spine' or the 'Company') (TSXV: ASG) (OTCQB: ASAPF), a leader in innovative spinal implant technology, is proud to announce that its DEXA-C™ system has now been successfully used in more than 1,500 cervical spine procedures across the United States. This milestone underscores the ongoing adoption and trusted performance of the DEXA Technology™ platform, which was honored with the Best Technology in Spine Award. Aurora's proprietary DEXA Technology™ is the world's first spinal implant platform intentionally engineered to match a patient's bone density across the entire BMD continuum, including normal, osteopenic, and osteoporotic bone. Each implant is designed with an open, porous structure that promotes osseointegration and vascularization, and mimics the lattice architecture of human cancellous bone — resulting in a similar modulus of elasticity and better biomechanical compatibility. 'DEXA-C™ provides surgeons with the first tool that truly puts bone quality at the center of implant selection,' said Trent Northcutt, President and CEO of Aurora Spine. 'With over 1,500 successful surgeries behind us, the data is clear: this technology improves outcomes. And now, we're ready to take it even further as we build out our sales efforts for this platform technology and prepare launch for our second DEXA Technology-enabled product the DEXA-L, which will be rolled out later this year.' Aurora Spine is excited to announce the upcoming Q4 2025 launch of DEXA-L™, a standalone Anterior Lumbar Interbody Fusion (ALIF) system built on the same award-winning DEXA platform. Like DEXA-C™, the DEXA-L™ implant is designed to address the challenges of spinal fusion in patients with varying bone densities — especially those with osteoporosis. For decades, spinal implants were primarily developed for patients with healthy bone stock. However, these implants have demonstrated reduced performance in patients with low bone density, where traditional designs may lack sufficient bone-implant contact and fail to achieve long-term fixation. DEXA Technology™ directly addresses this clinical gap, offering a smart, density-matched solution for today's diverse patient population. Aurora continues its mission to bring personalized spine solutions to market, with a growing DEXA portfolio that includes cervical, lumbar, and sacroiliac fusion systems. For more information on DEXA Technology™ and Aurora's full product line, visit About Aurora Spine Aurora Spine is focused on bringing new solutions to the spinal implant market through a series of innovative, minimally invasive, regenerative spinal implant technologies. Additional information can be accessed at Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Statements This news release contains forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Aurora Spine, including, without limitation, those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Information" in Aurora Spine's final prospectus (collectively, "forward-looking information"). Forward-looking information in this news release includes information concerning the proposed use and success of the company's products in surgical procedures. Aurora Spine cautions investors of Aurora Spine's securities about important factors that could cause Aurora Spine's actual results to differ materially from those projected in any forward-looking statements included in this news release. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ unilaterally from those expressed in such forward-looking statements. No assurance can be given that the expectations set out herein will prove to be correct and, accordingly, prospective investors should not place undue reliance on these forward-looking statements. These statements speak only as of the date of this press release and Aurora Spine does not assume any obligation to update or revise them to reflect new events or circumstances. Company Contacts: Aurora Spine Corporation Trent Northcutt President and Chief Executive Officer (760) 424-2004 Chad Clouse Chief Financial Officer (760) 424-2004 Investor Contact: Adam Lowensteiner Lytham Partners (646) 829-9702 Email: asapf@
